Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Paragonix Technologies, a pioneer in organ transplant technologies, organ offer, and surgical recovery services, today announced the successful...
-
MISSISSAUGA, Ontario, July 22, 2026 (GLOBE NEWSWIRE) -- Traferox Technologies, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the...
-
TolerogenixX Receives EMA Orphan Drug Designation for MIC-Lx, Strengthening its Regulatory Pathway for Lead Program in Kidney Transplantation
-
Clinical data presented at the 2026 American Transplant Congress demonstrates controlled hypothermic preservation with LIVERguard can safely extend cold ischemic time without compromising...
-
Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart
-
Paragonix Technologies will present new clinical findings related to its liver and kidney preservation systems through multiple scientific presentations at ATC 2026.The research being presented...
-
Prospective, multicenter trial will evaluate a novel preservation technique utilizing the Paragonix SherpaPak® for DCD (Donation after Circulatory Death) hearts. Paragonix Technologies and UW Medicine...
-
Eledon to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at ATC
-
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Paragonix Technologies, a pioneer in organ transplant technologies and services, announces utilization of the Paragonix LIVERguard® Donor Liver...
-
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights